ABclonal is a technology company.
ABclonal is a technology company.
ABclonal has raised $190.0M across 1 funding round.
ABclonal has raised $190.0M in total across 1 funding round.
ABclonal has raised $190.0M in total across 1 funding round.
ABclonal's investors include DST Global, Sequoia Capital China.
ABclonal Technology is a Massachusetts-based biotechnology company founded in 2011 that develops and manufactures high-quality, cost-effective research reagents and custom services for life science researchers, in vitro diagnostics (IVD), and pharmaceutical companies.[2][3] It offers a broad portfolio including over 10,000 self-manufactured antibodies (notably recombinant rabbit monoclonal antibodies via its proprietary SMab™ Single B cell platform), ELISA kits, proteins, enzymes, molecular biology reagents, NGS library preparation kits, and custom services like antibody development, engineering, and protein expression.[1][2][3] ABclonal serves academic researchers studying areas such as cancer, epigenetics, DNA damage & repair, infectious diseases, and neurodegenerative disorders like Parkinson's, while also supporting industrial R&D with tailored solutions for drug discovery and IVD product development; its growth is evidenced by global R&D centers, ISO9001/ISO13485 certifications, next-day shipping for in-stock items, and rapid portfolio expansion.[1][2][3]
ABclonal Technology was established in 2011 as an innovative biotech firm with a mission to empower biomedical innovation through reliable research tools.[2] Headquartered in Woburn, Massachusetts (500 W Cummings Park, Ste. 6500), it has expanded with R&D centers worldwide and a UK hub in Swansea, reflecting a focus on global technical advancement in protein science and molecular biology.[1][2][3] The company's idea emerged from listening to scientists' needs, translating feedback into products via state-of-the-art platforms like SMab™ for single B cell-based monoclonal antibody discovery, which incubates B cells in vitro for high-affinity recombinant antibodies.[1][2] Early traction came from building a catalog of 10,000+ items and custom services, with pivotal growth in recombinant antibodies and NGS kits, positioning it as a dynamic provider amid rising demand for reproducible reagents.[1][3]
ABclonal rides the wave of advancing biomedical research amid surging demand for precise, reproducible reagents in precision medicine, drug discovery, and diagnostics, fueled by trends like single-cell analysis, epigenetics, and neurodegenerative disease studies (e.g., Parkinson's, muscle development).[1][3][4] Its timing aligns with post-pandemic growth in NGS, IVD raw materials, and custom antibodies, where market forces favor affordable, high-throughput tools over traditional methods—enabling faster innovation for researchers tackling cancer, infectious diseases, and DNA repair.[2][3] By providing scalable platforms like SMab™, ABclonal influences the ecosystem through accelerated publications (e.g., myoblast differentiation, PD research) and support for pharma R&D, democratizing access to advanced antibodies and reducing development timelines.[1][4]
ABclonal is poised for continued expansion by scaling its SMab™ platform and NGS/IVD offerings amid booming biotech R&D investments. Trends like AI-driven antibody design, personalized medicine, and global health challenges (e.g., aging populations driving neurodegeneration research) will shape its trajectory, potentially through more partnerships and portfolio diversification. Its influence may evolve from reagent supplier to key enabler in therapeutic antibody pipelines, solidifying its role as a cost-effective innovator in life sciences.[1][2]
ABclonal has raised $190.0M across 1 funding round. Most recently, it raised $190.0M Series D in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $190.0M Series D | DST Global, Sequoia Capital China |